Another relatively new SARM is becoming all the rage. RAD140 is available to the masses for research purposes only, at the moment. It’s likely that will change in the coming couple of years as Radius Health, a public pharmaceutical company is formulating and developing a form of RAD140 for therapeutic purposes. Currently code named Testolone, Radius Health’s version of RAD140 will be used to supplement testosterone replacement in individuals that struggle to produce adequate amounts of testosterone.
That appears to just be the tip of the iceberg. RAD140 has the potential to be much more that that.
Perhaps the reason RAD140 is thought to have so much potential is because of the complete lack of side effects found to date. With more research performed in regards to RAD140 than most SARMs, you’d think there would be some definitive adverse side effects that many studies recognize. That’s simply not the case though.
In 2010, a fabulously thorough study was completed that outlined the design, synthesis, and characterization of RAD140. The study took a deep dive in to each of the exact makeup and effects RAD140 had on various cells. Since then, a variety of more specified studies have been making progress focusing on the more specific benefits and potential touched on in the 2010 study.
In April of 2014 study published in the Endocrine Society’s Journal of Endocrinology, a team led by Anusha Jayaraman established that RAD140 is a neuroprotective substance. In other words, RAD140 can be used to protect nerve cells against damage and degeneration. The ongoing efforts to build on these findings can possibly lead to the end of degenerative nerve disorders and wildly improve therapy treatments regarding nerve paralysis!
More recently, a study completed in 2017 found that RAD140 inhibits the growth of androgen and estrogen receptors, specifically when applied to breast cancer models. According to the published research, “Oral administration of RAD140 substantially inhibited the growth of AR/ER+ breast cancer patient-derived xenografts.” The thought that we could leverage RAD140 to help in the fight of breast cancer is obviously very exciting. Perhaps we could tweak it and inhibit any region of the body that is suffering from cancer.
Most SARMs require some sort of intravenous method of bioavailability. RAD140 is actually fairly unique in this regard as oral bioavailability is a real possibility. Swallowing substances is the preferred method of ingestion nowadays as there is no risk of infection from needle contamination involved. Additionally, when was the last time a doctor prescribed you a shot to treat your ailments? How about a pill, tablet, or powder? Exactly. Pills, tablets, and powders that can be consumed to treat ailments are the preferred method because of ease of use.
It sure seems that the possibilities are endless. RAD140 still doesn’t appear to have any negative side effects but the FDA (Food and Drug Administration) will require a lot more research to be completed before they green light medicinal research projects on humans similar to Radius Health’s solution. If you want to help speed the process, get some RAD140 in a 100% contaminate-free, 30ml vial and attack cancer or nerve damage research with enthusiasm and peace of mind.
- Chris P. Miller, Maysoun Shomali, C. Richard Lyttle, Louis St. L. O’Dea, Hillary Herendeen, Kyla Gallacher, Dottie Paquin, Dennis R. Compton, Bishwabhusan Sahoo, Sean A. Kerrigan, Matthew S. Burge, Michael Nickels, Jennifer L. Green, John A. Katzenellenbogen, Alexei Tchesnokov, Gary Hattersley, et al. “Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.” ACS Med Chem Letter., U.S. National Library of Medicine, 2 Dec. 2010, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018048/.
- Anusha Jayaraman, Amy Christensen, V. Alexandra Moser, Rebekah S. Vest, Chris P. Miller, Gary Hattersley, Christian J. Pike, et al. “Selective Androgen Receptor Modulator RAD140 Is Neuroprotective in Cultured Neurons and Kainate-Lesioned Male Rats.” Journal of Endocrinology., U.S. National Library of Medicine, April 2014, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959610/.
- Yu, Z, et al. “Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 15 Dec. 2017, www.ncbi.nlm.nih.gov/pubmed/28974548.
- Miller, C P, et al. “Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 2 Dec. 2010, www.ncbi.nlm.nih.gov/pubmed/24900290.